Skip to content
Subscriber Only
Opinion
Max Nisen

Biotech Should Cash In Its Trump Bump

The window to sell new shares is open again, but for how long?

Biotech's Trump-inspired rally has been a major source of relief for the industry, in more than one way.

With the Nasdaq Biotech Index (NBI) up nearly 10 percent since Election Day -- including the biggest one-day jump in biotech shares in nearly a decade -- companies can now tap equity markets for funding more successfully. That's a big relief for companies depending on share sales to fund years of losses as they develop drugs.